Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Financings

Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt

By The Northwire Desk — AI Analysis Jan 05, 2026 · 17:31 DOSE · 0.145 Rapid Dose Therapeutics Corp.
DOSE · Price

Executive Summary

  • Rapid Dose Therapeutics Corp. will issue 362,708 common shares at a deemed price of $0.13 to satisfy $47,153.98 of accrued interest on its amended and restated secured convertible notes dated December 1 2025.
  • The share issuance is expected no later than January 15 2026 and the shares will be subject to a hold period of four months and one day.
  • This action follows an extension of maturity dates for $3,084,445 of promissory notes and related warrants to November 30 2026.

Key Details

  • Notes Background: Amended and restated secured convertible notes issued on December 1 2025; interest rate 18% per annum, compounded monthly.
  • Accrued Interest Paid in Shares: $47,153.98 of accrued interest will be satisfied by issuing 362,708 common shares at a deemed issue price of $0.13 per share (CSE closing price on December 31 2025).
  • Issuance Timeline: Shares to be issued no later than January 15 2026.
  • Hold Period: Issued shares subject to a lock‑up expiring four months and one day after issuance.
  • Financing History: Original private placement financing (2023) closed all four tranches, raising $3,134,445 principal amount of notes and 15,672,225 warrants at $1.00 per unit.
  • Extension Agreement: Noteholders with $3,084,445 of promissory notes agreed to extend maturity to November 30 2026; accompanying 15,422,225 warrants extended to the same date.
  • Prepayment Rights: Company may prepay the notes with ten days’ notice without additional bonus.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Rapid Dose Therapeutics Corp.

Apr 13, 2026 · 09:51

Manufacturing Upgrades Mask Capital Burn Risks Amid Debt Maturity

Production / Operations Apr 06, 2026 · 16:31

Rapid Dose’s routine interest‑payment share issuance underscores ongoing dilution pressure as debt terms remain burdensome.

Financings Mar 26, 2026 · 18:34

Rapid Dose talks up IP wins, market expansion

Production / Operations Mar 26, 2026 · 09:10

Rapid Dose Therapeutics Reinforces Strategic Strength and Global Growth Trajectory

Production / Operations Mar 05, 2026 · 18:16

Rapid Dose receives Indian patent for QuickStrip

M&A / Property Mar 05, 2026 · 10:09

Rapid Dose Therapeutics (DOSE) (RDTCF) Secures Patent for QuickStrip(TM) Nicotine Oral Film Targeting $38B Smoke-Free Nicotine Market

M&A / Property